April 23, 2024
Gibson, Dunn & Crutcher LLP advised leading global investment firm KKR on its investment into Immedica Pharma, a pharmaceutical company headquartered in Stockholm focused on the commercialisation of medicines for rare diseases and specialty care products.
KKR’s investment will support Immedica Pharma’s continued growth and expand the company’s global reach. Immedica Pharma’s existing owner, Nordic healthcare investment firm Impilo, will reinvest to become equal owners alongside KKR.
KKR is investing in Immedica Pharma through its KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies. KKR has a long track record of supporting health care companies globally, having invested approximately $19 billion in the sector since 2004.
The Gibson Dunn team advising KKR was led by European Co-chair of Private Equity Wim De Vlieger, and comprised counsels Jakob Egle and Manjinder Tiwana and associates Rosie Maguire, Scarlett Travers, and Romain Tourenne (Corporate, London). The team also included partners Ali Nikpay and Attila Borsos and associates Ben Nunez, Elsie Stone and Annabel Green (Antitrust, London); and partner Sandy Bhogal and associate Bridget English (Tax, London).